
Despite the fact that Christophe Bourdon was only appointed CEO at Orphazyme as recently as March 2021, he will be leaving the firm on April 1, 2022.
In a notification to the stock exchange, Orphazyme reports that he will be leaving to become CEO at Leo Pharma.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app